Travera Terms of Use and Testing Services

1. Agreement and scope

These terms govern use of Travera, Inc.’s website and requests for eligibility review, laboratory testing, and related coordination services (“Travera,” “we,” “us”). Entry-page acceptance begins that process; it does not order testing, consent to collection, authorize charges, or require a purchase. Testing requires physician approval and an order, your acceptance of scope and total price, and applicable clinical consents and financial arrangements. Website rules bind browsing only to the extent permitted by applicable law.

Your accepted quote and billing terms control testing scope and price. MDI’s terms govern its platform; the clinical provider’s terms and consents govern its care. These terms do not replace or amend those agreements; applicable law and the relevant agreements resolve overlap. Travera is a HIPAA covered entity. Our Notice of Privacy Practices governs protected health information; our Privacy Policy and applicable consumer-health-data notice address other personal information. Acknowledging a notice is not consent to optional analytics, an email subscription, or a HIPAA authorization.

2. Who may request services

The standard online intake is for the patient identified in the form to review and personally accept. A caregiver may help the patient complete it, but must not accept as though they are the patient. If someone needs to act or sign as the patient’s legal representative, contact Travera before proceeding so identity, authority, and the appropriate consent process can be addressed. Caregiver status alone does not authorize treatment consent, financial commitments for the patient, or records access. We may verify identity, authority, location, and service eligibility. Minor-patient requests require an approved consent process.

Keep diagnosis, treatment, medication, care-team, location, and contact information accurate and current. Availability depends on clinical appropriateness, physician orders, sample requirements, and geographic and legal restrictions. The intake’s combined patient-identity and results acknowledgment confirms who is personally accepting and explains report access, physician-review scope, and follow-up. It does not itself authorize testing, sample collection, charges, disclosure to a caregiver, or optional marketing, and it does not waive patient rights. Required clinical consents, scope-and-price acceptance, and any optional marketing authorization remain separate.

3. Physician review and clinical responsibilities

Testing requires an appropriate order from a licensed physician. Eligible requests may go to a telehealth physician licensed for the patient’s location, or the treating oncologist or physician may order directly. A request does not guarantee approval or availability.

M & D Integrations, Inc. DBA MD Integrations (MDI) provides the portal and facilitates access to a licensed clinician through the applicable professional entity. That clinician exercises independent medical judgment about eligibility and ordering and is responsible for the clinical services provided. Travera performs the laboratory analysis and provides testing logistics, reporting, and laboratory support. Any required telehealth or treatment consent is obtained through the clinical provider’s process; these Travera terms do not replace it. A website visit or navigator conversation alone does not create a physician-patient relationship. The included physician eligibility and ordering review determines whether testing is appropriate and should be ordered. A routine follow-up consultation to discuss results is not included. The ordering MDI clinician has access to the report in the portal; access does not confirm review or interpretation. Telehealth review for testing does not replace ongoing oncology care. Nothing in these terms limits a clinician’s duties under applicable law or the clinical provider’s agreements.

Your treating clinician decides whether and how to use the report alongside your full clinical picture. Please share your report with your treating oncologist and arrange follow-up; Travera’s laboratory support does not prescribe treatment. Do not start, stop, or delay treatment based solely on website content or a report. Our website and coordination service are not emergency services; call 911 or seek emergency care when needed.

4. Testing and its limitations

Nova Select measures living immune-cell responses to selected immunotherapy drugs in blood. RapidSelection measures living tumor-cell responses to physician-selected therapies in tissue or malignant fluid. Expanded panels, deeper profiling, and longitudinal testing are included only as specified in your accepted order and quote.

These tests provide functional laboratory observations, not a guarantee of clinical benefit or a prediction that every tested drug will or will not work for you. Either panel may include drugs used off-label or not approved for your disease. Results do not establish a drug’s approval for your cancer, its safety or effectiveness for you, its availability, or insurance coverage. Testing more drugs does not guarantee a better clinical outcome. Results must not be the sole basis for diagnosis or treatment. As described on the current website, Nova Select and RapidSelection are laboratory-developed tests developed and performed by Travera, Inc., CLIA #22D2229321, and have not been cleared or approved by the FDA.

5. Collection, samples, and timing

After ordering and consent, we coordinate the agreed collection materials and logistics; mobile blood draws depend on availability. Follow collection, handling, and shipping instructions. The clinician or collection provider explains procedure risks and obtains required consent. These terms do not authorize biopsy or other invasive procedures.

Samples may be unsuitable, delayed, damaged, insufficient, or yield too few reportable results to meet the billing threshold. We explain next steps, including appropriate complimentary recollection under the Billing Policy. A complimentary repeat collection and laboratory attempt adds no fee, but reaching three unique ordered reportable drugs across the original and repeat attempts makes the full original agreed price payable. Each drug counts once. For standard Nova Select, two initial drug results plus one additional drug result from recollection means $4,000 total is payable. If the combined count remains zero to two, or you decline recollection with zero to two initial results, you owe nothing, including associated physician review and collection fees. We explain and record your acceptance of this possible billing outcome before recollection. New orders or expanded testing require separate advance disclosure and agreement.

Published turnaround times are estimates subject to sample receipt and acceptance, complete ordering information, and laboratory requirements. We will communicate material delays. Do not postpone an urgent care decision while waiting for a report. Samples and laboratory records are handled under applicable requirements and the testing consent. For Nova Select, the planned combined “Panel Choice & Testing Consent” document records the selected panel, price, and consent to collection and clinical testing before those activities begin. Any required additional provider consent remains separate. Acceptance of these Terms or of clinical testing does not itself authorize research participation or unrestricted secondary use. Research uses require an applicable lawful basis and any required separate permission or approval.

6. Prices, payment, and no-reportable-result policy

We confirm the ordered panel, total price, included physician review and collection charges, and applicable billing-policy version before testing and record your acceptance. We collect no advance payments or deposits and issue no invoice before the applicable report is released as defined in the Billing Policy. The basic Nova Select panel includes five commonly used immunotherapy drugs for $4,000 total. Nova Select Extended Panel includes those five drugs plus seven additional drugs, for twelve drugs and $6,000 total ($2,000 more). Each total includes MDI physician eligibility and ordering review and blood collection, shown as separate invoice line items within the total, not as additional charges. Other services have their own prices disclosed and accepted before testing. If the MDI clinician approves the extended panel, you may select the basic or extended panel before testing; we confirm that the physician order matches your selection. Approval to order laboratory testing is not approval or a prescription to use any tested drug.

For Nova Select, Nova Select Extended Panel, and RapidSelection, three or more unique ordered drugs with reportable results means the full agreed panel price; zero to two means you owe nothing for the panel or its associated physician review and Travera-arranged collection. For basic Nova Select, this means $4,000 total for three or more reportable drugs and $0 for zero to two. For Nova Select Extended Panel, three or more reportable drugs from the twelve ordered drugs means $6,000 total, even if none of the seven additional drugs is reportable; zero to two means $0. “No result = no bill” means fewer than three reportable drug results for these panels. Missing drug results do not reduce the price; there is no proration or tiered pricing. A valid result showing little or no response counts if it meets laboratory quality requirements. Nova Fit and Immune Profiling require a reportable product-level result, issued and released as defined in the Billing Policy, for billing; the three-drug threshold does not apply. If testing is not approved, no testing, associated MDI physician review, or Travera-arranged collection charge is passed to the patient.

Travera’s Billing Policy forms part of these Terms and governs reportability, complimentary recollection, invoice timing, and credits or refunds. The policy version presented when you accept your testing scope and price applies to that order; later changes do not retroactively change your billing terms. Travera does not currently accept medical insurance. Payment plans and financial assistance may be available by request under separate disclosed terms, with no advance payments.

Payment is due 30 calendar days after the applicable report-release date defined in the Billing Policy, unless an approved payment arrangement provides otherwise. We notify the patient or financially responsible party of that date and deadlines. The Billing Policy sets recollection, invoice-hold, corrected-report, and refund rules. Payment does not depend on a treating oncologist receiving or interpreting the report or on a results consultation. Charges must be disclosed before acceptance; no undisclosed fee may defeat the no-charge promise. Contact us promptly about cancellation or billing. No subscription or automatic repeat-test charge is created; payment plans require separate agreement.

7. Reports and follow-up

For requests initiated through MDI, your report is made available in your patient portal and is accessible to the ordering MDI clinician. For other physician orders, we send the report to the ordering clinician. Please share your report with your treating oncologist and arrange follow-up. Providing your oncologist’s name or permission to share results does not confirm that they received the report or agreed to review it. We may coordinate sharing as legally permitted, but do not guarantee your treating oncologist’s receipt, review, or interpretation. You may also request a copy through our records process, subject to identity verification and applicable access rights, without accepting marketing.

Promptly update clinician and delivery details and contact Travera if you cannot access your report or need help obtaining a copy. We handle corrections under laboratory procedures and notify recipients as required. Helping with intake or supplying contact details does not itself authorize caregiver portal or report access; permission or representative authority must be established as applicable. Your rights to obtain and use your records remain intact. For patients using the MDI ordering pathway, a cover letter accompanying the report restates access and follow-up information. The cover letter explains the process; it does not interpret findings or replace clinical follow-up.

8. Service messages and optional marketing

We may contact you about inquiries, eligibility, collection, orders, reports, payment, and requested services, consistent with law and your preferences. Required channel permission is obtained separately. Keep contact details current and tell us if you need another communication method.

With your optional email preference, we may email people who completed testing or began intake without proceeding to testing. We may send information about Travera’s own health-related services, including longitudinal immune-system monitoring and repeat testing that you may discuss with your treating clinician when considering a treatment change. Qualifying communications about our own health services generally do not require a separate HIPAA marketing authorization; we obtain any authorization or consent required by applicable law before a use or disclosure that requires it. These terms, the combined intake acknowledgment, and MDI service-message permissions do not enroll you in these optional emails. You may unsubscribe at any time without affecting eligibility, testing, pricing, or report access. We honor earlier opt-outs and authorization limits; a policy change does not override your recorded choices. Email enrollment does not authorize marketing calls or texts, advertising-platform targeting, testing, or charges.

9. Website content and acceptable use

Website content is general information, not personalized medical advice. You may share it for lawful personal use or care-team discussion with attribution and without misrepresentation. Travera or its licensors retain rights in the site, branding, software, and protected content, without limiting your rights in health information or sharing reports for care.

Do not compromise security, access others’ information without authority, submit malicious or unlawful material, impersonate others, or use prohibited automated extraction. Protect account credentials and promptly report misuse. We may restrict access for misuse or security threats while preserving required records access and accepted-service obligations.

Independent sites and services have their own terms. Changing or suspending website features does not end obligations for accepted orders, records, or refunds.

10. Disclaimers and limits

Where legally permitted, general website content is provided as available, without guarantees of uninterrupted or error-free access. Clinical outcomes are not guaranteed. These terms do not disclaim laboratory or provider duties, excuse failure to perform agreed services, or waive nonwaivable patient or consumer rights.

To the extent legally permitted, Travera is not liable for indirect, incidental, special, consequential, or punitive damages arising solely from use of the general informational website. This exclusion does not apply to fraud, willful misconduct, gross negligence, personal injury, breach of confidentiality or data-protection duties, or liability that cannot lawfully be excluded. No broader clinical-services liability cap or mandatory arbitration agreement is established here.

11. Changes, disputes, and contact

We identify and communicate material changes and obtain renewed assent as required. Changes cannot retroactively alter accepted prices, expand authorizations, or modify existing orders without required agreement.

Massachusetts law governs where permitted, preserving mandatory protections under other applicable law. Unenforceability of one provision does not invalidate the remainder where lawful. Raising concerns with us does not waive regulatory complaints or available remedies.

Travera, Inc., Attention: Legal Department, 200 Boston Ave., Suite 1500, Medford, MA 02155. Email: info@travera.com. Telephone: 781-874-0808.